Creative Biotherapeutics, LLC announced continued progress in the preclinical development of CBT300, an investigational biologic therapeutic candidate. The program is being advanced through research, validation, and regulatory preparation focused on mechanisms associated with drug resistance, immune evasion, recurrence, and metastasis. This development matters because cancer recurrence and treatment resistance remain significant barriers to long-term survival, particularly for aggressive cancers.
The company is led by Anita Davidson, DPT, a healthcare professional with decades of experience supporting patient recovery, and her husband and scientific collaborator, Dr. Don Davidson, a biochemist with over thirty-five years of experience in drug development and oncology research. For Anita Davidson, the work is rooted in clinical reality, having recently lost a sixteen-year-old patient to a form of brain cancer that returned rapidly despite treatment. "There are losses that stay with you," Davidson said. "You remember the families, the hopes, and the urgency. That child is a reason I keep working." This personal motivation underscores the human impact driving the scientific pursuit.
Dr. Don Davidson said the company's development efforts are guided by a focus on biological mechanisms that contribute to treatment failure and disease return. "Cancer outcomes are often shaped by recurrence and resistance," he said. "Our development work focuses on mechanisms associated with relapse and treatment escape so future therapies can be evaluated with that reality in mind." The scientific focus on these mechanisms is critical because they represent fundamental challenges in oncology where many treatments eventually fail.
CBT300 is being developed as a multi-mechanism biologic candidate intended to be evaluated for its potential to interfere with drug-resistance pathways, immune-evasion mechanisms, and cellular processes associated with recurrence and metastasis. The company stated that research and validation are ongoing and that development decisions are guided by a disciplined, evidence-based approach. Davidson also emphasized tolerability as an important development consideration. "Patients and families live with the full burden of treatment," Davidson said. "We want development pathways that respect patients and are guided by real-world experience." This patient-centric approach could influence how future cancer therapies are developed and evaluated.
Creative Biotherapeutics is preparing remaining components required to support advancement toward FDA-regulated clinical trials, including continued research, validation, and regulatory readiness. "We are working diligently toward entering clinical trials," Dr. Davidson said. "Progress has to be earned through data, discipline, and integrity." The company reports issued and pending patents related to its platform and lead program. The goal is to advance toward FDA-regulated clinical trials through an evidence-based development pathway.
Creative Biotherapeutics is sharing information publicly to support awareness among patients, clinicians, and members of the scientific and healthcare communities regarding CBT300 and its development progress. The company welcomes mission-aligned collaboration inquiries related to the responsible development of CBT300. For more information, visit the official website. Collaboration inquiries can be directed here with a brief description of organizational role and interest area. CBT300 is investigational and has not been approved by the U.S. Food and Drug Administration.
